CHRS (Coherus Oncology) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHRS Coherus Oncology Inc CHRS
42 GF Score
Price $1.27
GF Value $0.94
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Coherus Oncology Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Coherus Oncology's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

CHRS vs NAUT, AVXL, SLNCF: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Coherus Oncology's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Margin of Safety % (DCF Dividends Based) falls into.


CHRS
42GF Score
Coherus Oncology Inc CHRS
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coherus Oncology (CHRS) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of $1.27 is trading 35.1% above its estimated GF Value™ of $0.94. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for CHRS:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $0.94 vs. price of $1.27 (35.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges 8C5:Germany
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score

Get the complete analysis for CHRS

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price
$0.94
GF Value